Impact Factor
4.89
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
14.05
8,891 total citations
h5-index
114
h5 depth signal
Cited share
91.2%
622 of 682
Total citations
8,891
Citation footprint
Metric signal
14.72
External metric anchor
Self-citation
1.5%
130 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
2,357
Italy
501
United States
501
Germany
150
France
99
Citing Fields of Research
Cancer & Development
1,483
Oncology
832
Noncoding RNA
823
Cancer, Autophagy & Apoptosis
781
Immunology
657
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,580
Articles tracked across the journal lifetime
Indexed publication set
682
622 cited publications
Last 12 months
300
25.0 publications/month
Open access share
100.0%
300 OA publications in the last year
Leading citing country
China
2,357 citing publications
Leading citing field
Cancer & Development
1,483 citing publications
Latest tracked publication
21 October 2026
10 recent records available
Coverage & Indexing History
v16n1,Mar. 1997-
v16, Mar. 1997-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Cancer & Development
Cancer, Autophagy & Apoptosis
Oncology
Noncoding RNA
Issuing & Sponsoring Bodies
Contributor
BioMed Central Ltd
Broad Categories
Neoplasms
Cancer, Autophagy & Apoptosis
Noncoding RNA
Cancer & Development
Immunology
Lung Cancer
MeSH Descriptors
Medical Oncology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1186/s13046-026-03847-8
Open DOI
Baseline and early changes in serum proteomic profiles predict anti-tumor activity in patients with advanced HPV-associated malignancies treated with novel combination immunotherapy
Background: Patients with advanced human papillomavirus (HPV)–associated malignancies who do not respond to immune checkpoint blockade have limited treatment options. Combination immunotherapy consisting of an HPV16 therapeutic peptide c...
02
DOI 10.1186/s13046-026-03857-6
Open DOI
Protein acylation in cancer: from regulatory networks to precision therapeutics
Protein acylation comprises a diverse class of metabolite-responsive post-translational modifications that links cellular metabolic states to protein function and signaling. Beyond canonical acetylation, emerging acylation marks are dyna...
03
DOI 10.1186/s13046-026-03850-z
Open DOI
PLPP4+ CAFs drive cancer progression by promoting ECM deposition via ceramide-mediated H3K27ac modification and CREB3L1 activation
Background: Cancer-associated fibroblasts (CAFs) are the primary cellular source of extracellular matrix (ECM) in the tumor microenvironment (TME). Nevertheless, heterogeneity among CAF subsets results in substantial differences in their...
04
DOI 10.1186/s13046-026-03841-0
Open DOI
MiR-22-3p shapes glioblastoma radiation resistance and downregulates the DNA demethylase tumor suppressor TET1
Glioblastoma (GB) is an aggressive brain tumor characterized by marked radioresistance and poor clinical outcomes. MicroRNAs (miRNAs) are key post-transcriptional regulators implicated in tumor progression and therapeutic response. Here,...
05
DOI 10.1186/s13046-026-03856-7
Open DOI
Liquid biopsy identifies tumor-derived mir-302/367 cluster as a macrophage-reprogramming axis sustaining immune cold prostate cancer
Background: Despite extensive clinical investigation, immunotherapy has failed to demonstrate consistent clinical benefit in prostate cancer (PCa), largely due to the development of an immunologically cold tumor microenvironment that res...
06
DOI 10.1186/s13046-026-03852-x
Open DOI
Targeting SRF-activated aminopeptidase NPEPL1 with a novel small-molecule inhibitor offers a potential therapeutic strategy for hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Metabolic reprogramming play critical roles in HCC progression and treatment response, but effective therap...
07
DOI 10.1186/s13046-026-03858-5
Open DOI
TRIP13 protects LDHA from FBXW7-mediated degradation and drives glycolytic plasticity in colorectal cancer
Background: Metabolic plasticity enables colorectal cancer (CRC) cells to survive hypoxic and therapeutic stress. Lactate dehydrogenase A (LDHA) is a key regulator of glycolysis and lactate production, yet the mechanisms that maintain LD...
08
DOI 10.1186/s13046-026-03855-8
Open DOI
BRD4-S reprograms glutathione metabolism to reduce ferroptosis sensitivity and limits oxaliplatin response in gastric cancer
Background: Bromodomain-containing protein 4 (BRD4) exists as distinct isoforms with potentially different biological functions, but their roles in ferroptosis and chemotherapy response in gastric cancer (GC) remain poorly understood. He...
09
DOI 10.1186/s13046-026-03853-w
Open DOI
MyD88 sustains a metastasis-competent cell state by promoting integrin-mediated adhesion in melanoma
Background: Metastatic dissemination remains a major challenge in melanoma, as environmental cues can reshape tumor cell plasticity and promote transient states that enable invasion and colonization of distant organs. However, the tumor ...
10
DOI 10.1186/s13046-026-03818-z
Open DOI
Nutrient availability shapes tumour adaptation: a systems-level view in 3D lung adenocarcinoma models
Background: Cancer progression in non-small cell lung cancer (NSCLC) depends on the tumour cells’ ability to adapt to metabolic and mechanical limitations in heterogeneous microenvironments. How nutrient availability coordinates mitochon...
Bibliographical & Catalog Notes
Description based on: Vol. 2, no. 1 (Jan.-Mar. 1983); title from cover.
Print issues ceased with v.26 (2007).
Also issued online.